BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1756324)

  • 1. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
    Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
    Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
    Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J; Fehér I
    Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
    Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
    Rizzoli V; Mangoni L
    Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
    Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
    Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
    Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in patients with lymphoid malignancies receiving unpurged or mafosfamide-purged autografts.
    Carlo-Stella C; Mangoni L; Almici C; Meloni G; Mandelli F; Rizzoli V
    Behring Inst Mitt; 1991 Dec; (90):69-74. PubMed ID: 1801693
    [No Abstract]   [Full Text] [Related]  

  • 16. Hematopoietic growth factors: in vitro and in vivo studies in bone marrow transplantation.
    Rizzoli V; Carlo-Stella C; Mangoni L; Bonati A
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():270-7; discussion 277-8. PubMed ID: 2182739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
    Mumcuoglu M; Naparstek E; Slavin S
    Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.